Introduction
Adenovirus vectors have been employed to overexpress genes of interest in the central nervous system (CNS) with the ultimate objective of achieving effective therapeutic interventions to ameliorate ischemic insults, neurodegenerative conditions, and other brain disorders. Different genes and promoter systems have been utilized and various cell populations targeted, with neuroprotection achieved by transgene expression in rodent models of both Parkinson's disease [1] [2] [3] [4] [5] and cerebrovascular occlusion. 6, 7 Adenovirus vectors have been selected for such investigations because they can be purified to very high titer and offer the advantage of expressing transgenes in a broad range of cell types, both quiescent and actively dividing, including oligodendrocytes, astrocytes, neurons and ependymal cells. [8] [9] [10] [11] Furthermore, they allow expression over a relatively protracted time-period, with reports by some investigators of transgene expression in the brain up to 2 months. 1, [8] [9] [10] [11] For many studies adenovirus vectors have also been chosen on the basis of their perceived minimal cytotoxicity and limited immunogenicity. 10 This property, however, has come into question with a growing number of reports documenting significant cytopathic and inflammatory responses following vector infusion. 12 Injection of adenovirus vectors into mice causes a marked inflammatory response and infiltration of leukocytes at the site of delivery, as assessed by immunocytochemistry and flow cytometry. 13 It is now also evident that adenovirus vectors can elicit immune responses in the CNS both at the site of delivery and at synaptically connected distant sites, 14 and that inflammation is elicited directly by the virion particles rather than through the expression of new proteins encoded by the transgene. 11 Given the immunologically privileged nature of the CNS, however, it has been argued that intracranial vector delivery may not trigger a sufficient T cell response to elicit these reactions. 15 This relative immunologic isolation may indeed have accounted for earlier favorable assessments of the inflammatory properties of adenovirus vectors and the reports of persistent transgene expression of as long as several months following intracranial infusions. 16 Since different rat strains exhibit different immunologic responses to vector infusions, 11 it is possible that differences in the immune response by rodents to the Ad5 vector, which is predominantly a human virus strain, may be responsible for diminished inflammatory responses in rodents.
Even if proven minimally immunoreactive and cytotoxic in rodents, extension of promising viral vector strategies to clinical applications requires a re-evaluation of cytotoxicity and immunogenicity in primate CNS, which more closely approximates the human immunologic and cellular milieu. Rodents can be immunologically tolerant to antigens that readily trigger cellular and humoral responses in humans, an immunological difference that might be expected to be particularly true when comparing host responses with a modified human virus such as Ad5. Thus, it is essential to assess inflammatory and immune-mediated host responses to vector delivery before proceeding with an evaluation of the possible therapeutic efficacy of such interventions. Furthermore, few studies have included data concerning vector purity or particle ratio, thus making it difficult to compare levels of gene expression, cytotoxicity and host response. One study in the rhesus monkey using an adenovirus vector in doses ranging from 1.4 × 10 8 plaque forming units (p.f.u.) to 1.5 × 10 11 p.f.u., resulted in localized gliosis and necrosis, roughly correlating in severity with increasing dose. 17 In addition to governing levels of inflammation and cytotoxicity, the immunologic status of the host animal before vector exposure and the extent of the immune response mounted might also affect levels of gene expression. In rodents, it is clear that a strong inflammatory response in the brain is not sufficient to eliminate transgene expression, 11, 13 but this may not be true in primates. To evaluate both the efficiency and anatomical extent of adenovirus vector-delivered gene expression in primates and to assess whether inflammatory responses may be a determinant of levels of gene expression, we studied an adenovirus vector bearing the E. coli reporter gene, LacZ, which expresses ␤-galactosidase, after injection into the caudate nucleus in St Kitts green monkeys. The same titer and volume were used in each animal. The serum antibody humoral response of the animals before and after vector delivery and the inflammatory responses in the brain were examined post mortem. To determine whether decreasing inflammation with exogenous corticosteroids increases gene expression, 11 half of the monkeys were dexamethasone treated and half were untreated. Dexamethasone is a potent and wellcharacterized anti-inflammatory agent which exerts its major effects on the inflammatory response in the CNS by inhibiting the neuronal expression of cytokines and chemokines to prevent macrophage migration, 18 and by interfering with the function of transcription factors such as AP-1. 19, 20 Additionally, glucocorticoids act to prevent edema after surgery and head trauma. Following dexamethasone and viral vector administration, postmortem histology allowed both a quantification of the total number of cells targeted and a qualitative assessment of levels of host immune reaction. (Figure 1 ) was observed in seven of the 10 monkeys infused with the vector. Multiple cell types were infected by the adenovirus vector, with ␤-galactosidase activity seen in neurons, glia, and ependymal cells as assessed by morphology and reported previously in monkey brain. 21 Less than 1% of the labeled cells were in the ependyma of the lateral ventricle. The total number of labeled cells counted in each half brain of each monkey and the anterior/posterior extent of expression is shown in Table 1 . There was a significant anterior/posterior extent of expression from the site of injection, spanning up to 1.6 cm in one monkey. Needle tracts and an injection site were discernible in the counted hemispheres of all animals. There was a high degree of variability in levels of expression among individual monkeys, which was not accounted for by dexamethasone treatment (see Table 1 ). The mean number of ␤-galactosidase-positive cells in the dexamethasone-treated and untreated group was 120 012 ± 56 557 (standard error of the mean, s.e.m.) versus 162 320 ± 120 843 (s.e.m.) cells, respectively, under the conditions studied and with all monkeys included in the analysis (t = 0.32, df = 8, P = 0.79). If the two monkeys which were killed at 7 days were dropped from the analysis, the difference between the treatment groups was still insignificant.
Results

␤-Galactosidase expression
In contrast, the level of expression was closely correlated with the extent of infiltration of host immune mediators, and hence, local inflammatory response to vector infusion (Figures 2 and 3) . A qualitative ranked assessment of the extent of inflammatory response was made in eight animals for which brain sections were available (two were damaged and not sectioned), revealing a generally inverse relationship to the number of cells expressing ␤-galactosidase (Table 1 ) (P = 0.1, Spearman's rank correlation).
Routine hematoxylin and eosin (H&E) stained sections of the basal ganglia revealed focal chronic inflammatory infiltrate, particularly in the perivascular space. The degree of inflammatory infiltration was highly variable from animal to animal and from focus to focus. However, the caudate nucleus and internal capsule were predominantly involved in most cases. Demyelination was noted in and around the foci of inflammatory infiltrate, particularly in the internal capsule, where the myelination is abundant and demyelination, if any, was easily discerned on luxol fast blue stain (Figure 3 ). Macrophages were shown by immunohistochemistry for CD68. B cell and T cell lymphocytes were detected with immunohistochemistry for CD20 and CD3. The extent of cytotoxicity apparent from examination of H&E and luxol fast blue stained sections was confirmed by the intensity of immunostaining for CD20 and CD68, and CD3, markers of mononuclear cell infiltration (see Figure 2 ). LN-3, a marker of major histocompatibility complex class II receptors, also showed a similar relationship in this and in another study. 21 There were differences among animals in the extent of necrotic lesions observed at the site of injection, which were also generally correlated with the level of gliosis, necrosis, B cell, T cell and macrophage infiltration, and demyelination, as assessed by the neuropathologist who viewed the sections after the various stains and immunohistochemical reactions described ( Table 1) ever, was sufficiently small that it could not by itself account for the observed differences in the number of cells expressing ␤-galactosidase. High levels of apoptosis were present in monkeys showing the least ␤-galactosidase expression, compared with monkeys with the highest ␤-galactosidase expression and little apoptosis present (see Figure 4 ). All animals had positive adenovirus antibody titers before vector infusion. Titers did not change significantly following exposure to the vector except in one monkey, U030, which showed an increase (see Figure 5 ). This was also the animal in which the most pronounced neuropathology was observed.
Sera from all animals were screened for neutralizing antibodies to recombinant Ad5RSVlacz. Examples for positive control titers from a sheep, immunized with a regimen of three recombinant Ad5RSVlacz virus injections and a human serum (hu1), found to be positive for Ad5 neutralizing antibodies (out of three randomly screened samples obtained from the Yale Blood Bank), are shown in Figure 6 . The same monkey which had elevated serum antibody titers (UO30) showed a significant pre-immune 50% neutralizing antibody titer of 1:65. This titer increased significantly over the course of 4 weeks, displaying a neutralizing antibody titer of 1:240 (see Figure 6 ). All other animals had no detectable pre-immune Two animals were killed on day 7(*) the rest of the group on day 30 after vector injection. The means of ␤-galactosidase-positive cells in the dexamethasone-treated and the non-treated monkeys were not statistically different (see text). High levels of inflammatory infiltrate, as rated histologically by the neuropathologist and based upon all of the stains and inflammatory cell markers, CD20, CD3 and CD68, seemed to correlate with the lack of ␤-galactosidase expression. Extent of lesion, rated by the neuropathologist, indicates the amount of necrosis seen at the injection site. NA, tissues not available for examination due to technical problems in the preparations.
50% titer. However, several animals had detectable postimmune titers which were considered to be insignificant, eg animal S834 showed a 50% titer after 7 days of 1:60, animal U011 a titer of 1:80 after 4 weeks, and S985 a titer of 1:80. Comparison with our data for the human serum 1 shows the high sensitivity and the reliability of this neutralizing antibody assay.
Discussion
Consistent with previous reports, we found adenovirus vectors to be effective vehicles for gene delivery to the CNS, observing in excess of up to 6 × 10 5 targeted cells in one site. The anterior/posterior extent of expression exceeds that reported in rodent studies, which may be reflective of the comparatively large volume of vector stock infused together with the anatomic differences between rodents and primates. The distribution of ␤-galactosidase-positive cells represented contiguous zones of expression that appeared to be the result of vector diffusion rather than remote retrograde infection, but the latter possibility cannot be ruled out. Such retrograde infection is a well-established occurrence with the use of herpes simplex vectors 22 and has been documented in rat 1, 8 and monkey brain 21 using an adenovirus vector. In six of eight monkeys, expression persisted for the 1 month duration of the experiment. This finding is consistent with patterns of expression seen in rodents where ␤-galactosidase activity has been detected up to 2 months after infusion. 1, 9, 10, 15 There was no expression observed in one of the 1 week animals and two of the 1 month animals which was not reflective of time of animal death, but may instead reflect a particularly robust immune response. Indeed, the relationship between the number of ␤-galactosidase-expressing cells from animal to animal and the intensity of the immune response, suggests that inflammatory mediators can affect levels of vector expression in the brain. Two of the three animals showing no ␤-galactosidase expression, however, did not appear to have neutralizing antibodies to Ad6, Ad5, or the vector, Ad5RSVntlacZ. It has been suggested that the bacterial ␤-galactosidase transgene or expressed enzyme may be responsible for some inflammatory responses, 23 which might have occurred in these two monkeys.
Some of the reduction in expression seen in monkeys which exhibited heightened inflammatory responses may be attributed to the elimination of vector infected cells by T cell-mediated activity. 15 This may well have been the case, although there was also an additional component of tissue damage seen at the immediate site of injection in some animals which may have contributed to reductions in the count of ␤-galactosidase-positive cells. Given the limited extent of the lesions, however, they would not in themselves have entirely accounted for the reduced ␤-galactosidase-positive cell counts. Another component of the reduction in expression may arise from the unfavorable cellular environment induced by the inflammatory response. In mice, changes in the neuronal energetic and oxidative environment during local ischemia, achieved by occlusion of the middle cerebral artery, reduce gene expression; expression rebounds with reperfusion. 24 Likewise, Choi-Lundberg et al 1 demonstrated that there may be a down-regulation of protein and RNA in the absence of loss of vector DNA. Apoptosis in the vector injected brain regions of the monkeys showing the least ␤-galactosidase expression may play a role in the elimination of cells infected by the vector, induced by several possible pathways, including cytotoxic T lymphocyte activity, by cytokines, by other immune effector cells. [25] [26] [27] [28] The role of Ad5 early region E4 in the induction of p53-independent apoptosis suggests the possibility that an E1a, E3 and E4 deleted vector might avoid this damaging effect. 29, 30 Differences among monkeys in antibody titers against ␤-galactosidase may also have accounted for some of the variability. The use of contralateral brain sections, which required different processing and handling, to assess ␤-galactosidase expression and inflammatory cell markers within each animal may have served to exacerbate the impact of such variability on data interpretation, specifically with regard to the comparison of vector expression and the elicited immune response. To minimize this variability, contralateral sections were matched carefully, by slice thickness and section counts, to those with ␤- Dexamethasone administered at human immunosuppressive doses did not have a significant effect on the number of ␤-galactosidase-labeled cells. Although comparable doses of dexamethasone administered to rats blocks the cellular infiltration and neuropathic lesions seen following viral encephalopathies, 31 it may be that the primate immune system is more reactive to adenovirus vectors than that of the rodent where other immunosuppressive regimens have been studied. It has been demonstrated, for instance, that the administration of FK506, which acts by directly interfering with T cell activity, significantly prolongs transgene expression in mice. 32 Pretreatment with anti-CD40L antibody blunts the immune response to Ad vector and results in extended duration of expression and allows for re-dosing in the liver. 33 These strategies may be useful for the brain. It is not clear why some animals should mount a significant inflammatory response while others would not. In rodents subjected to repeated inoculations of adenovirus vector in the brain and then elsewhere in the body, all those that exhibit initial immune tolerance to vector delivery to the brain subsequently exhibited a T cellmediated inflammatory response both at the CNS infusion site and the new infusion site elsewhere in the body. 34 Thus, the host can become sensitized to the vector. In this investigation, all animals exhibited antibody titers to Ad6, a common adenovirus strain with immunocross-reactivity with Ad5RSVntlacZ, which suggested that each had been previously exposed to adenovirus.
However, only monkey U030 had neutralizing antibodies and a clear increase after vector exposure. This monkey not only showed no ␤-galactosidase expression at 1 month, but also showed the greatest inflammatory responses.
Absence of immunologically naive animals within the study population hampered a clear determination of the relationship between the degree of prior sensitization to the virus and the extent of vector expression. A consideration of absolute antibody titers within the previously sensitized animals, however, reveals no evidence of an inverse correlation between antibody titers and the number of cells expressing ␤-galactosidase, as might have been predicted if the degree of prior sensitization were an important determinant of the extent of vector transgene expression. There was also no appreciable relationship between level of antibody titers at the time of death and the number of cells expressing ␤-galactosidase or the extent of the inflammatory response.
In the sample of monkeys studied, adenovirus-derived vectors are clearly capable of eliciting significant inflammatory responses in the primate CNS, conflicting with earlier suggestions that the brain represents an immunologically privileged site that is less susceptible to inflammatory reactions triggered by vector delivery. 15 Rather, our results support rodent studies revealing CNS inflammatory responses 11 and other studies in primates demonstrating significant neutralizing antibody titers. 22 This investigation also suggests that the present adenovirus vector would not be an appropriate vector for gene transfer into the brain in a clinical setting where prevention of neuron death and therapeutic restoration of function are the primary objectives. Instead, this vector has been used for the delivery of antitumor genes in the clinical setting. [35] [36] [37] [38] Consideration of the prior immune Table 1 ). These results suggest that apoptosis may be a factor in the lack of ␤-galactosidase expression in U030. Scale bar = 50 m. response, the impact of concurrent or subsequent exposure to adenovirus, 34 and modulation of the immune responses would be important for any future clinical application of adenovirus vectors in the brain.
Figure 4 Apoptotic cells are abundant in the regions of perivascular infiltrates of monkey UO30 (a, b and d) from the caudate nucleus. A negative control of UO30 is shown in (c), from the same target region. (e) and (f) show lower and higher magnifications from brain sections of the caudate stained with the 'Apop Tag' kit of monkey T998, showing few stained nuclei. T998 showed 315 270 ␤-galactosidase containing cells (from
Figure 5 Adenovirus antibody titers of St Kitts (African) green monkey sera and a human reference sample (Hu2). The sera were collected before (pre-injection) and 4 weeks after (post-injection) of the vector into the caudate nuclei of animals indicated on the x-axis. Antibody titers were measured by ELISA using preparations of Ad5RSV nlLacZ or Ad6. Specificity of the anti-adenovirus core protein antibody response was verified in an ELISA competition assay. There was no significant difference in the titers of sera measured against Ad5 and Ad6 antigens. These data show that St Kitts green monkeys have elevated pre-immune adenovirus antibody titers. However, a significant increase in these titers after administration of the vector virus into the caudate nucleus was only observed in one case (U030). All other serum titers either remained unchanged or were reduced (T075 and T011). Numbers shown above the bars are the number of cells expressing ␤-galactosidase on one side of the monkey's brain.
Figure 6 Neutralizing antibody titers to Ad5RSVlacz in pre-immune and post-immune sera from animal UO30 are shown compared with a fetal bovine serum control (FBS). 50% titers are estimated to be 1:65 at the start of the experiment (M5) and 1:240 after 4 weeks (M10
14 Repetitive high-dose delivery of adenovirus vectors to pulmonary and hepatic tissue results in the activation of both cellular and humoral components of the immune system to limit transgene expression 39 with successful re-administration of vector only after immunosuppression. 40 Nevertheless, the significant number of cells expressing transgene seen in the majority of monkeys after 1 month suggest that this vector could be used to study the effects of various transgenes on neuronal function and neuropathology in the non-human primate CNS. Strategies to modify the Ad backbone to circumvent expression of viral proteins and thereby diminish immune responses include a temperature sensitive point mutation in the E2A region, 41, 42 removal of E4 43 or total gutting of all viral sequences in Ad5 except for the inverted terminal repeats and packaging signal. [43] [44] [45] The use of endogenous transgenes and cellular promoters might also minimize immune responses, improve long-term expression and minimize cytopathic effects. The use of an adequately sized group of monkeys, with variable genetic factors in this study, emphasizes that there are variables of the host response to vector administration that are not well understood and that do not correlate with pre-and post-delivery immune status. A better understanding of such variables might contribute to better vector design or screening of hosts to assure persistent expression without cytotoxic effects.
Materials and methods
Vector
The vector, designated Ad5RSVntlacZ, has been previously described. 46 Briefly, an E. coli ␤-galactosidase sequence with accompanying SV40 poly A signal was introduced into an E1a, E3 deleted replication deficient adenovirus sequence downstream of a RSV promoter, allowing propagation of the vector in a replication permissive cell line to obtain titers of 2 × 10 10 p.f.u./ml. Virus was amplified and purified according to standard procedures and was checked for contamination by replication competent Ad by PCR for E1 sequences and by plaquing on A549 cells. Recombinant virus titers were determined by plaquing on HEK 293 cells. There was no detectable wild-type virus (assay sensitivity is 1 in 1 × 10 9 particles), and the particle ratio was 60. Virions were suspended in PBS with 3% sucrose, stored in liquid nitrogen, and thawed on ice a few minutes before use.
Subjects and surgical procedure
Ten healthy adult male African (St Kitts) green monkeys, Cercopithecus aethiops sabaeus, were individually caged and fed daily at least 4% of body weight of jumbo high protein monkey chow (Lab Diet, PMI Feeds, St Louis, MO, USA) supplemented with locally grown fruits. Access to drinking water was unrestricted. For vector infusion surgery, monkeys were first sedated with ketamine (10 mg/kg), and then intravenous lines were placed for infusion of 0.9% sodium chloride and intravenous pentobarbital to maintain stage III surgical anesthesia. An endotracheal tube was placed and respiration monitored and assisted if needed throughout the procedure. The monkeys were placed into Kopf Instruments (Tujunga, CA, USA) stereotactic head holders, and the caudate nucleus was targeted bilaterally (coordinates: anteriorposterior +21.1 mm; lateral 4.0 mm and vertical 21.5 mm from ear bar zero). 30 l of vector stock containing 6 × 10 8 p.f.u. was microinfused bilaterally into the caudate nucleus through a stereotactically mounted 22-gauge spinal needle attached via polyethylene tubing (PE60) to a 100 l Hamilton syringe mounted on a microperfusion pump (Stoelting Instruments, Wood Dale, IL, USA). The rate of needle excursion for initial penetration to the injection site was 5 mm/min. After insertion of the needle, vector infusion was delayed for 1 min to allow rebound equilibration of parenchymal tissue. Vector was then infused over a 30 min period at a rate of 1 l/min, following which the cannula was unmoved for 1 min before slow withdrawal at 1 mm/min. This was repeated contralaterally, with the side of first injection randomized. The vector infusion titers, volume, and rates had been determined from a previous experiment. 21 Five of the 10 monkeys began receiving an immunosuppressive dose of dexamethasone (0.4 mg/kg i.m.) 1 day before microinfusion of vector. This daily dose was maintained until a taper to 0.3 mg/kg on day 6 after infusion, then 0.2 mg/kg on day 7, and 0.1 mg/kg on day 8. Dexamethasone was discontinued thereafter. A control group of five monkeys received no dexamethasone, but an equivalent number of control saline injections. Monkeys were treated immediately before surgery with 1.2 million units of penicillin G benzathine and penicillin G procaine suspension i.m., and post-operatively with iron dextran (1 ml i.m.) to boost red blood cell production. Monkeys received standard post-operative veterinary care. All recovered well from surgery and exhibited no unusual behaviors or any apparent adverse effects up to the time they were killed. The research protocol, facilities and animal care program complied with the US Guide for the Care and Use of Laboratory Animals. 47 Tissue collection and preparation One monkey from each group was killed at 7 days after vector infusion. The remaining eight monkeys were killed at 1 month after infusion. At the time of death each monkey was injected with intravenous sodium pentobarbital until loss of corneal reflexes. The brain was perfused through the aortic outflow with 3 l of ice-cold phosphatebuffered saline (PBS, with 1 U sodium heparin/ml) using a perfusion pump (Masterflex Pump, Cole Parmer Instrument, Barrington, IL, USA). The brain was then removed and further chilled in ice-cold saline for 10 min before being sliced into 4 mm coronal sections. The left side of each brain was immediately frozen in the nitrogen vapor of a liquid nitrogen containing cryotank at a rate of 2°C per minute as assessed by thermocouple for a total freezing time of 40 min. The right side of each brain was fixed in 4% paraformaldehyde in 0.1 m PBS, and then stored in PBS with 30% sucrose. Before vector delivery and at the time of death, blood was collected and plasma was frozen in liquid nitrogen to be evaluated for antibody titers to adenoviral strains.
Histology
Fixed cryoprotected sections were frozen and cut by microtome into 50 m sections, every 10th of which was stained for ␤-galactosidase activity, using the substrate Xgal (5-bromo-4-chloro-3-indoyl-␤-d-galactopyranoside). 48 Tissue-bound peroxidase was visualized by a diaminobenzidine (DAB, usually employed for immunocytochemistry, but found to be an effective background stain for assessing ␤-galactosidase activity) reaction (15 mg DAB, 165 l of 0.3% H 2 O 2 in 30 ml PB, 10-15 min), and individual cells with discernible nuclear localized ␤-galactosidase staining were counted in each section throughout the anterior and posterior extent of vector expression, with note made as to the site of needle track entry and vector infusion. Needle tracks were seen targeting the caudate nucleus bilaterally in every animal.
Quantification of ␤-gal expressing nuclei
Nuclei expressing the ␤-galactosidase protein (stained blue with X-gal histochemistry) were quantified using the NeuroLucidaTM Morphometry System (MicroBright Field, Colchester, VT, USA) and Nikon TE300 Eclipse microscope. 50 m mounted brain sections were placed on a motorized stage driven in the X, Y and Z planes. At 188 × magnification, the entire brain section was manually scanned for areas of blue nuclei. This was done by traversing the entire section in the X and Y planes until the full area containing blue nuclei was identified. Once the area was localized, it was outlined on the computer screen with a computer mouse using the 'contour' function at 476× magnification. The magnification was then increased to 952× and, using the 'Meander Scan' function, blue nuclei in each increment manually marked with a designated cursor symbol using a computer mouse. Different cursor symbols were used for blue nuclei located in the brain parenchyma and in ependymal cells lining the lateral ventricle. In cases where there was an aggregation of blue staining in which individual nuclei could not be discerned a different cursor symbol was used. Although these probably represented more than one infected cell, they were assigned a conservative value of one and added to the total of infected cells in the parenchyma. This procedure was continued throughout the entire contour area and then the number of blue nuclei in each 50 m section was multiplied by 10 to arrive at an estimate of the number of labeled cells per 500 m section of brain. These numbers were then summed to determine the total number of labeled cells in the target structure. This procedure provides a high magnification method for counting blue nuclei, in which nuclei are neither doubly counted nor are they missed. Counts were made by observers blinded as to dexamethasone treatment. A preliminary report of these data was based upon counts by a second blinded observer manually counting ␤-galactosidase-labeled cells with a 200× magnification. 49 The earlier count yielded a lower number of labeled cells than the more accurate NeuroLucida method reported here, but the conclusions regarding the effects of dexamethasone and the relationships among the number of cells expressing ␤-galactosidase, antibody titers and inflammatory responses were the same.
Neuropathological analysis
Frozen stored brain slices from the opposite side of the brain of the experimental animals were thawed and fixed overnight in 10% neutral buffered formalin, dehydrated and paraffin embedded following standard cytological procedures. Serial sagittal sections (5 m) from these embedded brain slices (approximately 250 m thick) were prepared and stained with either H&E or with luxol fast blue (LFB) and matched to the comparable sections on the opposite side of the brain. Histology was scored without any knowledge of the treatments of any animal, by a neuropathologist (YHK), using an empirical semiquantitative scale describing the inflammatory response. The overall intensity of the inflammatory infiltrate was scored with: 0, none; 1+, little; 2+, mild; 3+, moderate; and 4+, heavy infiltrate. Analysis also included the type of inflammatory cell present and the location.
Immunohistochemistry
For immunohistochemical evaluation of specific immune cells, serial sections of these paraffin embedded brain slices were deparaffinized, and stained with human antibodies specific for CD68, CD20, CD3 (all from DAKO, Carpenteria, CA, USA) and HLA-DR (LN-3; Cell Marque, www.cellmarque.com), following the manufacturer's recommendation for the pretreatment of paraffin embedded sections.
After the appropriate pretreatment (deparaffinization under increased pressure and/or trypsin treatment) tissue sections were incubated in 0.1m Tris buffer containing 0.01% Triton-X-100, 1% BSA, followed by a 30 min incubation with normal goat serum, followed by an overnight incubation with the appropriate primary antibody at 4°C. In preliminary studies, we verified the cross-reactivity of these primary human antibodies with the appropriate inflammatory monkey cell targets. Sections were further processed and finally stained with a horseradish-peroxidase kit (Vector Labs, Burlingame, CA, USA). After counterstaining with H&E, sections were examined by a neuropathologist (YHK).
Serum titers of adenovirus antibodies
Monkey serum anti-Ad5 and Ad6 antibody titers were determined with ELISA assays. Plates (96 well) were coated overnight at 4°C, with either an inactivated Ad5RSVntlacZ preparation (1:1000; Gene Transfer Vector Core, University of Iowa, IA, USA) or a commercial adenovirus antigen preparation, adenoid 6 (1:1000; Chemicon, Temecula, CA, USA) in a 0.05 m sodium carbonate buffer, pH 9.6. Triplicate sets of the monkey serum samples were transferred to the microtiter wells (200 l, diluted 1:100) and incubated at room temperature for 1 h. Serum levels of adenoviral antibodies were detected with a two-stage detection anti-monkey IgG horseradish-peroxidase conjugate after color development, assays were read at 450 nm in a multichannel microtiter plate reader. Specificity of the anti-adenoviral core protein antibody response was verified in an Elisa competition assay.
Adenovirus neutralizing antibody assay
Neutralizing antibody titers in monkey sera were determined using a modification of the microtiter neutralization analysis on HeLa cells, as previously described. 3 First, 20 000 HeLa cells were seeded into 96-well plates in 200 l DMEM, 10% FBS. Serial dilutions of monkey serum in 96-well round-bottom titer plates were mixed with 2 × 10 8 particles/100 l Ad5RSVlacz (Gene Transfer Vector Core, University of Iowa) and incubated at room temperature for 30 min. Aliquots of these serum/virus mixtures were transferred on to the near confluent HeLa cell layers and incubated at 37°C, 95% air/5% CO 2 for 1 h, followed by the addition of 150 l DMEM medium, supplemented with 10% FBS. Detection of ␤-galactosidase levels was quantified with a Galacto-light Plus kit (Tropix, Bedford, MA, USA), following the recommendations of the manufacturer. Negative controls consisted of wells without virus being added. Serial dilutions of fetal bovine serum served as 100% controls. The large number of samples created in these 96-well plate formats was measured using a TR717 standard microplate luminometer (generously provided by PE Biosystems, Norwalk, CT, USA) attached to a computer. Results are expressed as 50% titers (the reciprocal dilution, that gives a 50% inhibition of the maximum ␤-galactosidase expression).
Detection of apoptotic cells using ApopTag
The presence of fragmented DNA within dying cells, a hallmark of apoptosis, was determined using the ApopTag Kit (Oncor, Gaithersburg, MD, USA). For apoptosis detection, deparaffinized brain sections were digested with proteinase K (200 g/ml) for 30 min, rinsed in PBS, and incubated in 3% hydrogen peroxidase to inhibit endogenous peroxidase. After additional rinses, sections were incubated briefly in equilibration buffer followed by a 120 min incubation in working strength terminal deoxynucleotidyl transferase (TdT) mixed with reaction buffer (digoxigenin-11-UTP) at 37°C in a humidified chamber. The TdT enzyme was used to incorporate a digoxigenin tag on the 3Ј-OH ends of apoptotic DNA. The reaction was terminated by exposure to working strength washing solution for 30 min at 37°C, followed by one rinse with PBS and incubation with anti-digoxigenin-peroxidase for 30 min. Apoptotic cell nuclei were visualized after developing the horseradish peroxidase stain and mounting with a coverslip, following the manufacturer's directions. Positive controls included sections exposed to DNAse (3 g/ml) for 15 min at room temperature. Negative controls consisted of identical slides, which were exposed to distilled water instead of the TdT enzyme, followed by the remainder of the identical procedure.
